CD19 and B-cell non-Hodgkin lymphoma: In the presence of mCTRP9, anti-CD19 CAR-T cells exhibited significantly CD107a degranulation (Fig. 7P,Q) and stronger cytolytic activity (Fig. 7R) against B-cell lymphoma, suggesting an enhanced cytotoxicity.